CLINICAL TRIALS PROFILE FOR DABIGATRAN ETEXILATE MESYLATE
✉ Email this page to a colleague
All Clinical Trials for DABIGATRAN ETEXILATE MESYLATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01976507 ↗ | Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism | Completed | Boehringer Ingelheim | Phase 4 | 2013-10-01 | The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures. |
| NCT01976507 ↗ | Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism | Completed | Vanderbilt University | Phase 4 | 2013-10-01 | The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures. |
| NCT01976507 ↗ | Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism | Completed | Vanderbilt University Medical Center | Phase 4 | 2013-10-01 | The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency ablation, or cryoablation procedures. |
| NCT02102633 ↗ | Drug Interaction Study Between Bosutinib And Dabigatran | Completed | Pfizer | Phase 1 | 2014-05-01 | The study evaluates the effect of a single oral dose of bosutinib on the single dose pharmacokinetics of dabigatran, a p-glycoprotein substrate, in healthy subjects. |
| NCT02945020 ↗ | A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants | Completed | Janssen Research & Development, LLC | Phase 1 | 2016-11-10 | The purpose of this study is to evaluate the effect of steady-state concentrations of odalasvir (ODV), as a single agent or in combination with simeprevir (SMV), on the single-dose pharmacokinetics of dabigatran etexilate in healthy participants. |
| NCT03495739 ↗ | Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers | Unknown status | Huons Co., Ltd. | Phase 1 | 2018-02-01 | A randomized, open-label, single-dosing, 2x2 crossover study, the safety and pharmacokinetics of RDG-17012 with Pradaxa® in healthy male volunteers |
| NCT03495739 ↗ | Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers | Unknown status | Huons Co.,Ltd. | Phase 1 | 2018-02-01 | A randomized, open-label, single-dosing, 2x2 crossover study, the safety and pharmacokinetics of RDG-17012 with Pradaxa® in healthy male volunteers |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DABIGATRAN ETEXILATE MESYLATE
Condition Name
Clinical Trial Locations for DABIGATRAN ETEXILATE MESYLATE
Trials by Country
Clinical Trial Progress for DABIGATRAN ETEXILATE MESYLATE
Clinical Trial Phase
Clinical Trial Sponsors for DABIGATRAN ETEXILATE MESYLATE
Sponsor Name
